V

Vetoquinol

Develops and markets veterinary medicines

Website

Overview

Vetoquinol is a global animal health company that develops and markets medicines and health products for pets and livestock. Its products are used to treat diseases, prevent illness, and support animal well-being, distributed through a network of subsidiaries and partners in about 24 direct countries with products available in around 100 countries. Core operations include research, development, and commercialisation of veterinary pharmaceuticals and health solutions for both companion and farm animals. What sets Vetoquinol apart is its long family-led history and steady international expansion, including an IPO in 2006 to accelerate growth, which has helped it build a widespread, multi-country presence. The company’s goal is to improve animal health globally by bringing effective veterinary products to markets around the world and expanding access through direct operations and partnerships.

Work here?Claim your company

About Vetoquinol

Simplify's Rating
Why Vetoquinol is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Healthcare

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Paris, France

Founded

1933

Get referred to Vetoquinol

See people who can refer or advise you

Simplify Jobs

Simplify's take

What believers are saying

  • H1 2026 sales rose 3.4% constant-currency to €259.3 million, with net income up 22%.
  • U.S. sales jumped 13.1% constant-currency in H1 2026, Vetoquinol’s largest market.
  • Gross margin reached 77.1%, and management is preparing several new product launches for 2027.

What critics are saying

  • Asia-Pacific sales fell 4.2% constant-currency in H1 2026, signaling weak regional execution.
  • Currency swings and product-line simplification cut reported H1 2026 sales growth to 0.7%.
  • If 2027 launches disappoint, Vetoquinol remains a low-growth niche vendor vulnerable to margin compression.

What makes Vetoquinol unique

  • Vetoquinol’s Essentials now generate two-thirds of sales, giving it a higher-margin core.
  • The company pairs veterinary drugs with practice software like Command Centre ACT.
  • Family control and a pure-play animal-health focus keep capital allocation unusually consistent.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

N/A

N/A

Industry Average

Funded Over

1 Rounds

Acquisition funding comparison data is currently unavailable. We're working to provide this information soon!
Acquisition Funding Comparison Coming Soon

Benefits

  • Health Insurance
  • Disability Insurance
  • Paid Vacation
  • Commuter Benefits
  • Wellness Program
  • Professional Development Budget
  • Training Programs

Stock Price

Growth & Insights and Company News

6 month growth

2%

1 year growth

3%

2 year growth

3%
Yahoo Finance
Oct 28th, 2026
Vetoquinol nine-month sales rise 3.9% to $431M as third quarter jumps 10.4%

Vetoquinol, the French animal health group, reported nine-month sales of €399 million, up 3.9% on a reported basis and 5.4% at constant exchange rates. Currency moves cut sales by €6.1 million. Third-quarter sales rose 10.4% to €140 million (9.6% at constant rates). Essentials products, its core segment, grew 13.9%. At constant rates in the quarter, sales rose 8% in Europe, 11% in the US, and 23% in Asia-Pacific and the rest of the world. They fell 1% in the Americas excluding the US. Essentials made up 64.9% of nine-month sales, against 63.6% a year earlier. Vetoquinol will publish annual sales on January 14, 2027.

Animalytix
Sep 15th, 2026
Fountain Report Excerpts sep 15, 2026.

Fountain Report Excerpts sep 15, 2026. Fountain Report Excerpts September 15, 2026 * Chewy reported second-quarter net income of $80.5 million, up from $62 million in the prior year period. Net sales in Q2 were $3.33 billion, up from $3.1 billion in the prior year period. For the first half of 2026, net sales were $6.7 billion, up from $6.2 billion in the prior year period, and net income was $175.3 million, up from $124.4 million in the first half of 2025. * Vetoquinol returned to growth in the first half of 2026, with sales of €259 million ($301 million), up 3.4% at constant exchange rates. Sales in the U.S. market - the company's largest - rose by 13.1% over the first half of the year. Sales of companion animal products grew by 4.1% at constant exchange rates to €188 million ($218 million), accounting for 72.6% of the company's total sales. Sales of products for farm animals totaled €71 million ($82.5 million), representing 27.4% of sales, up +1.9% at constant exchange rates. * In the 1870s, horses were the lifeblood of North American cities, which relied on tens of thousands of workhorses to power daily life. Then, in late 1872 and into 1873, a devastating outbreak of horse flu - known as the Great Epizootic - swept across the continent. The tragedy catalyzed revolutions in medicine, animal rights and transportation, and is the subject of an upcoming book from MIT Press, "Nary a Horse Left Standing."

EC Assets
Sep 11th, 2026
Vetoquinol shares jump on 22% first-half profit increase.

Vetoquinol shares jump on 22% first-half profit increase. September 11, 2026 at 10:00 GMT EC Assets Editorial Vetoquinol shares surged significantly following the French animal health group's report of a 22% increase in first-half net income. The company also demonstrated strong cash flow generation during the period. This performance marks a return to growth for Vetoquinol in the first half of fiscal 2026. Vetoquinol's net income reached €30.5 million in the first half of 2026. This figure represents 11.8% of total sales for the period. The company's sales rose 3.4% at constant exchange rates to €259.3 million. MarketScreener reported revenue of €259m. Cash flow generation totaled €59 million. The growth was driven by strong performance in the U.S. market. Sales in the U.S. market increased by 13.1% in the first half. The company's results were achieved in an uncertain international environment. Vetoquinol Animal Health Sources: investing.com, morningstar.com, marketscreener.com, tipranks.com, app.dealroom.co.

Yahoo Finance
Sep 10th, 2026
Vetoquinol H1 2026: Sales reach $293M (+3.4%), US market surges 13.1% as essentials drive growth

Vetoquinol, a French animal health company, reported sales of €259 million for the first half of 2026, up 3.4% at constant exchange rates and 0.7% on a reported basis. Essential Products sales reached €169 million, growing 3.7% at constant exchange rates. The company posted earnings before interest and tax of €45 million, representing 17.3% of sales. Net income totalled €30 million, or 11.8% of sales. Cash flow generation was €59 million. Growth was driven by strong performance in the US market, where sales rose 13.1% in the first half. Essential Products now account for two-thirds of total sales. The company said it is preparing several new product launches.

Yahoo Finance
Apr 28th, 2026
Vetoquinol Q1 2026 sales flat at $141M amid currency headwinds and product simplification

Vetoquinol, a French animal health company, reported first-quarter 2026 sales of €125 million, down 4.3% on a reported basis but flat at constant exchange rates. Excluding currency effects and a product line simplification programme, sales increased 1.2% year-on-year. Exchange rate headwinds reached €5.2 million, primarily affecting the United States and India. The product line simplification programme impacted sales by €1.7 million. Essential products sales totalled €83 million, stable at constant exchange rates, whilst complementary products grew, driven by strong US performance. US sales rose 15.6% at constant exchange rates to €28 million. Companion animal products represented 71% of sales at €93 million, whilst farm animal products totalled €38 million. The company described 2026 as a transition year ahead of new product launches in 2027.

Recently Posted Jobs

Sign up to get curated job recommendations

Vetoquinol is Hiring for 18 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs